ribociclib

FDA Drug Profile — KISQALI

ribociclib is listed in the FDA National Drug Code directory with 7 NDC codes, marketed under brand name including KISQALI. Available dosage forms: tablet, film coated, powder.

Drug details

Generic Name
ribociclib
Brand Names
KISQALI
Application Number
NDA209092
Sponsor
Novartis Pharmaceuticals Corporation
NDC Codes
7
Dosage Forms
TABLET, FILM COATED, POWDER
Routes
ORAL
Active Ingredients
RIBOCICLIB SUCCINATE

Indications and Usage

1 INDICATIONS AND USAGE KISQALI is a kinase inhibitor indicated: in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. ( 1 ) for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer in combination with: an aromatase inhibitor as initial endocrine-based therapy; or fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy. ( 1 ) 1.1 Early Breast Cancer KISQALI is indicated in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. 1.2 Advanced or Metastatic Breast Cancer KISQALI is indicated for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer in combination with: an aromatase inhibitor as initial endocrine-based therapy; or fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.